AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Decoy Therapeutics Inc. Common Stock
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG00740LLF3
0.97▼ 0.06 (-5.83%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
Financial Highlights
Revenue (TTM)
—
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
Trading Information
Previous Close
1.03
Day's Range
0.96 – 1.04
52-Week Range
0.53 – 13.51
Volume
37.0K
Avg Volume
4.5M
Share Statistics
Shares Outstanding
Employees
11
Exchange
XNAS
Listed
2015-01-29
Share count as of August 12, 2026

Decoy Therapeutics Inc. Common Stock (DCOY) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Decoy Therapeutics Inc. Common Stock (DCOY)
What is Decoy Therapeutics Inc. Common Stock's Market Cap?
Decoy Therapeutics Inc. Common Stock's Market Cap is $635.5K, based on as-reported figures from SEC (XBRL) filings.
What is Decoy Therapeutics Inc. Common Stock's Enterprise Value?
Decoy Therapeutics Inc. Common Stock's Enterprise Value is -$7.7M, based on as-reported figures from SEC (XBRL) filings.
What is Decoy Therapeutics Inc. Common Stock's EV / EBITDA?
Decoy Therapeutics Inc. Common Stock's EV / EBITDA is 0.5×, based on as-reported figures from SEC (XBRL) filings.
What is Decoy Therapeutics Inc. Common Stock's Net Income (TTM)?
Decoy Therapeutics Inc. Common Stock's Net Income (TTM) is -$14.4M, based on as-reported figures from SEC (XBRL) filings.
What is Decoy Therapeutics Inc. Common Stock's EBITDA?
Decoy Therapeutics Inc. Common Stock's EBITDA is -$14.8M, based on as-reported figures from SEC (XBRL) filings.
What is Decoy Therapeutics Inc. Common Stock's Diluted EPS (TTM)?
Decoy Therapeutics Inc. Common Stock's Diluted EPS (TTM) is -22.05, based on as-reported figures from SEC (XBRL) filings.
What is Decoy Therapeutics Inc. Common Stock's Net Debt?
Decoy Therapeutics Inc. Common Stock's Net Debt is -$8.3M, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · DCOYAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Grant Revenue———
YoY growth————
Operating expenses:
Research and development
General and administrative
Total operating expenses
% of revenue1155.8%———
Loss from operations
% of revenue-1155.8%———
Interest income and other, net
Net loss
% of revenue-1042.8%———
Net loss per share attributable to common stockholders - basic—
Net loss per share attributable to common stockholders - diluted—
Total net loss per share - basic—
Total net loss per share - diluted—